

March 12, 2024

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
**The Manager – Listing,**  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Ref: Scrip Code: 543322**

**Ref: Scrip Name: GLS**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our disclosures dated March 6, 2024 in relation to transfer of 6,73,89,944 equity shares representing 55% of the issued and paid-up equity share capital of the Company from Glenmark Pharmaceuticals Limited (“GPL”) to Nirma Limited (“Nirma”) pursuant to the share purchase agreement dated September 21, 2023 among the Company, GPL and Nirma. The transfer of the remaining 2,45,05,435 equity shares representing 20% of the issued and paid-up equity share capital of the Company has been completed, and closing under the share purchase agreement is complete.

This is for your information and records.

**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**